Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor-Negative: ASCO Guideline Update.

Beverly Moy,R. Bryan Rumble,Steven E. Come,Nancy E. Davidson,Angelo Di Leo,Julie R. Gralow,Gabriel N. Hortobagyi,Douglas Yee,Ian E. Smith,Mariana Chavez-MacGregor,Rita Nanda,Heather L. McArthur,Laura Spring,Katherine E. Reeder-Hayes,Kathryn J. Ruddy,Paul Unger,Shaveta Vinayak,William J. Irvin,Avan Armaghani,Michael A. Danso,Natalie R. Dickson,Sophie S. Turner,Cheryl L. Perkins,Lisa A. Carey

Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor-Negative: ASCO Guideline Update.

2021

PURPOSEThis guideline updates recommendations of the ASCO guideline on chemotherapy and targeted therapy for patients with human epidermal growth factor receptor 2–negative metastatic breast cancer...

Keywords:

Cancer research
Endocrine system
Chemotherapy
Hormone receptor
Medicine
Human Epidermal Growth Factor Receptor 2
Metastatic breast cancer
Targeted therapy
human epidermal growth factor receptor
Guideline

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations